Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Descriptor ID |
D009190
|
| MeSH Number(s) |
C15.378.190.625
|
| Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 8 | 0 | 8 |
| 1997 | 5 | 2 | 7 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 5 | 1 | 6 |
| 2001 | 2 | 0 | 2 |
| 2002 | 9 | 1 | 10 |
| 2003 | 3 | 2 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 5 | 1 | 6 |
| 2006 | 3 | 0 | 3 |
| 2007 | 4 | 2 | 6 |
| 2008 | 2 | 1 | 3 |
| 2009 | 10 | 4 | 14 |
| 2010 | 4 | 1 | 5 |
| 2011 | 6 | 0 | 6 |
| 2012 | 7 | 0 | 7 |
| 2013 | 8 | 1 | 9 |
| 2014 | 9 | 1 | 10 |
| 2015 | 11 | 0 | 11 |
| 2016 | 9 | 4 | 13 |
| 2017 | 12 | 2 | 14 |
| 2018 | 7 | 1 | 8 |
| 2019 | 7 | 0 | 7 |
| 2020 | 8 | 1 | 9 |
| 2021 | 3 | 1 | 4 |
| 2022 | 10 | 0 | 10 |
| 2023 | 14 | 0 | 14 |
| 2024 | 8 | 7 | 15 |
| 2025 | 11 | 2 | 13 |
| 2026 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. J Clin Oncol. 2026 09 10; 44(26):2529-2542.
-
Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study. Ann Rheum Dis. 2026 Oct; 85(10):2033-2043.
-
Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12; 147(11):1168-1177.
-
Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets. Leukemia. 2026 Mar; 40(3):649-660.
-
FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome. J Clin Invest. 2026 Jan 16; 136(2).
-
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
-
Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s). Haematologica. 2026 06 01; 111(6):2070-2079.
-
Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology Group. Am J Hematol. 2026 01; 101(1):70-78.
-
Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
-
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 08; 9(13):3370-3380.